Experts Warn Menopause Misinformation Is Compromising Women's Care

Experts warn that misinformation and unnecessary hormone testing are harming menopause care, emphasizing the need for evidence-based practices and clinical diagnosis.
Recent discussions in leading medical publications highlight a growing concern about the proliferation of misinformation surrounding menopause and its impact on women's healthcare. Experts emphasize that many over-the-counter menopause services currently available are largely unnecessary and do not enhance clinical outcomes. This surge in commercial menopause interventions raises questions about the reliability of the information provided and potential biases influenced by profit motives.
A key issue identified is the common promotion of routine hormone panel testing for menopausal symptoms. These tests, often costing hundreds of dollars, are marketed as essential for tailoring hormone therapy but lack solid clinical justification. Current evidence indicates that hormone testing during perimenopause and menopause does not reliably predict treatment benefits, menstrual cycle changes, or safety for discontinuation of contraception.
Major clinical guidelines from organizations like the British Menopause Society, NICE, and ACOG reinforce that menopause is a clinical diagnosis based on symptoms such as irregular periods and hot flashes, without the need for hormone level testing. Despite this, many women are now presenting with comprehensive hormone panels ordered by wellness or online providers, leading to the use of unregulated compounded hormone preparations. These customized treatments pose safety concerns, including inconsistent hormone levels that could potentially cause abnormal cell growth or cancer in the uterine lining.
The authors argue that until definitive, individualized hormone targets are established, commercial hormone testing offers a false sense of precision and may contribute to unnecessary treatments. They suggest that the normalization of hormone panel testing signals broader issues, including the commercialization of women’s health and a departure from evidence-based practice.
Ultimately, effective menopause management should focus on listening to women’s symptoms and responding based on clinical response and patient preferences rather than relying on numbers and commercial tests. The article calls for greater adherence to evidence-based guidelines and cautions against the influence of profit-driven healthcare practices in this sensitive phase of women’s health.
Source: https://medicalxpress.com/news/2025-08-menopause-misinformation-experts.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Hope in Lymphoma Treatment: Terbium-161 Radioimmunotherapy
Researchers at PSI have developed a targeted radioimmunotherapy using terbium-161 to effectively combat lymphoma, offering new hope for precise and effective treatment options.
Insights from Feline Disease May Shed Light on Long COVID in Humans
New research from UC Davis explores how a severe cat disease caused by coronavirus may provide critical insights into long COVID in humans, with implications for immune recovery therapies.
Allopurinol Recognized as the First Orphan Drug for Marfan Syndrome Treatment
The EMA has designated allopurinol as the first orphan drug for treating Marfan syndrome, opening new avenues for managing this rare connective tissue disorder with vascular complications. Ongoing research explores its potential to prevent life-threatening aortic aneurysms.
Redefining the Public Health Workforce: Embracing a More Inclusive and Broader Framework
A new study advocates for a broader, more inclusive definition of the public health workforce, emphasizing impact over job titles to strengthen health systems and address complex community challenges.